Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD8<sup>+</sup>CD38<sup>+</sup> T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates.

Blood neoplasia·2026

Same author

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026

Same author

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026

Same author

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026

Same author

Practical Management of Bispecific Antibodies in Multiple Myeloma.

JCO oncology practice·2026

Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026

Search research articles

Related Experiment Video

Updated: May 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Smoldering multiple myeloma: present position and potential promises.

Nishant Tageja¹, Elisabet E Manasanch, Neha Korde

¹Multiple Myeloma Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

European Journal of Haematology

|October 12, 2013

Summary

Smoldering multiple myeloma (SMM) is a precursor to symptomatic myeloma (MM). Early intervention in SMM may delay progression or eradicate plasma cell clones, offering clinical benefit.

Keywords:

carfilzomib flow cytometry lenalidomide multiple myeloma plasma cell dyscrasia smoldering myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: May 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

Hematology
Oncology
Clinical Research

Background:

Smoldering multiple myeloma (SMM) definition and understanding have evolved over 30 years.
Progression risk to symptomatic myeloma (MM) varies significantly among patients.
Myeloma progression is a continuous process, not a sudden event, with potential early end-organ damage.

Purpose of the Study:

To explore the evolving understanding of SMM.
To investigate the continuous nature of myeloma progression.
To evaluate the potential benefits of early intervention in SMM.

Main Methods:

Utilizing epidemiologic, molecular, flow cytometry, and radiological techniques.
Leveraging contemporary antimyeloma therapies with manageable toxicities.
Employing molecular-cell-based measures to detect minimal residual disease.

Main Results:

Transformation to MM involves a series of overlapping events.
Advanced therapies can achieve deep and durable responses.
Minimal residual disease can be assessed using molecular-cell-based methods.

Conclusions:

Early intervention in myeloma precursor disease may offer clinical benefits.
Intervention could potentially delay disease progression.
Eradication of plasma cell clones is a potential therapeutic goal in early myeloma.